Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Int. j. morphol ; 35(1): 259-264, Mar. 2017. ilus
Artigo em Inglês | LILACS | ID: biblio-840964

RESUMO

Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.


Kruppel-like factor 6 (KLF6) is a member of the family of Kruppel transcription factors, this plays an important role in the regulation of cell growth, differentiation and angiogenesis. Rosiglitazone is a PPARy agonist drug, its antitumor effect has been described in models of breast and colon cancer. The aim of this study is to evaluate the level of expression of KLF6 in Caco2 cells treated with Avandia. For this a Immunofluorescence was performed, the Caco2 cells were cultured and treated with Rosiglitazone, another group was treated with Rosiglitazone and GW-9662, inhibitor for Immunofluorescence an anti-KLF6 antibody and a secondary antibody coupled to Alexa-488 was used . Cells were observed in a fluorescence microscope and images were processed. The results show that KLF6 is expressed in the cytoplasm of cells Caco2. Compared to treatment with Avandia, KLF6 increases its expression in the cytoplasm. When cells were treated with GW-9662 inhibitor, an expression of KLF6 in the nucleus was observed. KLF6 expression in the cytoplasm of cells Caco2, could be explained by the knowledge of splicing variants SV1 and SV2, these abnormally accumulate in the cytoplasm and promotes cell growth. It is concluded that in untreated Caco 2 cells, KLF6 is expressed in the cytoplasm. Compared to treatment with Rosiglitazone, KLF6 upregulated in the cytoplasm and compared to treatment with the inhibitor, KLF6 is expressed in the nucleus of Caco 2 cells.


Assuntos
Humanos , Adenocarcinoma/metabolismo , Antineoplásicos/farmacologia , Neoplasias do Colo/metabolismo , Fatores de Transcrição Kruppel-Like , Tiazolidinedionas/farmacologia , Apoptose , Células CACO-2 , Linhagem Celular
2.
Int. j. morphol ; 30(3): 1115-1131, Sept. 2012. ilus
Artigo em Espanhol | LILACS | ID: lil-665535

RESUMO

El cáncer colorrectal (CCR) constituye el segundo tipo de cáncer más frecuente en la población europea. Actualmente no existe biomarcadores moleculares que se pueden utilizar para la detección temprana del cáncer de CCR. KLF6 es un supresor tumoral relacionado con varios tipos de cánceres. Nuestra hipótesis plantea que KLF6 puede ser un excelente marcador en el diagnóstico precoz de CCR. Para estudiar la implicancia de KLF6 en el CCR, se seleccionaron 15 biopsias de cada estadio (T1,T2 y T3) de los archivos del Servicio de Anatomía Patológica del Hospital Central de la Defensa Gómez-Ulla, las cuales presentaban áreas de tejido afectado (tumor) y áreas sin afectación (no tumorales). Para ello se realizó un estudio histológico, inmunohistoquímico y RT-PCR, basada en la expresión de 3 genes, Ki67 y p53 como marcadores positivos y KLF6 como marcador en estudio. Los resultados mostraron que la expresión de KLF6 está directamente relacionada con el aumento de la malignidad celular en los adenocarcinomas, corroboradas por las RT-PCR, observándose la aparición progresiva de formas de procesado alternativo, no correspondiente a KLF6. Esta proteína, se expresó tanto a nivel citoplasmático como nuclear en los primeros estadios T1 y T2, para desaparecer a nivel nuclear en el estadio más avanzado (T3). Concluimos que KLF6 es un buen marcador tumoral de CCR, debido a que muestra patrones crecientes de expresión a nivel citoplasmático y decrecientes a nivel nuclear...


Colorectal cancer (CRC) is the second most common type of cancer in the European population. Currently there molecular biomarkers that can be used for early detection of cancer of CRC. Is a tumor suppressor KLF6 associated with several types of cancers. Our hypothesis is that KLF6 can be an excellent marker for the early diagnosis of CRC. To study the implication of KLF6 in CRC, we selected 15 biopsies of each stage (T1, T2 and T3) from the archives of the Pathology Department of Defense Central Hospital Gómez-Ulla, which had areas of affected tissue (tumor) and unaffected areas (non-tumor). This study was performed histological, immunohistochemical and RT-PCR, based on the expression of three genes, markers Ki67 and p53 as positive and as a marker in KLF6 study. The results showed that the expression of KLF6 is directly related to increased malignancy cell adenocarcinomas, corroborated by RT-PCR, showing the gradual emergence of alternative forms processing, corresponding to no KLF6. This protein was expressed both cytoplasmic and nuclear in the early stages T1 and T2, disappearing at the nuclear level in the most advanced stage (T3). KLF6 conclude that a good CRC tumor marker because it shows patterns of expression level increased cytoplasmic and nuclear level decreasing...


Assuntos
Humanos , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Fatores de Transcrição Kruppel-Like/metabolismo , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Proteínas Proto-Oncogênicas/metabolismo , Adenocarcinoma/genética , Diagnóstico Precoce , Fatores de Transcrição Kruppel-Like/genética , Imuno-Histoquímica , Biomarcadores Tumorais , Neoplasias Colorretais/genética , Valor Preditivo dos Testes , Proteínas Proto-Oncogênicas/genética , Reação em Cadeia da Polimerase em Tempo Real
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA